AMSTERDAM — The SAVOR-TIMI 53 study in 16 000 patients has confirmed the efficacy of the DPP-4 inhibitor, saxagliptin, for controlling glycaemia in type II diabetes but has failed to show a benefit in terms of cardiovascular outcomes. At the European Society of Cardiology Annual Congress Dr Deepak Bhatt MD, Professor of Medicine at Harvard Medical School and Chief of Cardiology, VA Boston Healthcare System Brigham and Women’s Hospital explains that this agent should be a useful addition in second and third line treatment.
SAVOR-TIMI 53 study: saxagliptin had better glucose control than placebo but no cardiovascular benefit
Further reading
Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...
Atrial fibrillation is prevented by exercise and life-long endurance athletes do not face the same elevated risks of stroke and heart disease from...
AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of having a...
AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of having a...
AudioMedica News Young adults less likely to be diagnosed with hypertension than over 60s Play Episode Pause Episode Mute/Unmute Episode Rewind 10...
AudioMedica News More cardiac deaths in the winter — no matter the climate Play Episode Pause Episode Mute/Unmute Episode Rewind 10 Seconds 1x Fast...